Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome

NCT00220402 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00220402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00220402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2004
Completion date
July 31, 2007
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder syndrome